{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:41:46Z","timestamp":1791362506683,"version":"4.3.1"},"reference-count":61,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T00:00:00Z","timestamp":1684195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2023,6,13]]},"abstract":"<jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Differentiating dementia due to small vessel disease (SVD) from dementia due to Alzheimer\u2019s disease (AD) with concomitant SVD is challenging in clinical practice. Accurate and early diagnosis of AD is critical to delivering stratified patient care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>\n                      We characterized the results of Elecsys\n                      <jats:sup>\u00ae<\/jats:sup>\n                      cerebrospinal fluid (CSF) immunoassays (Roche Diagnostics International Ltd) in patients with early AD, diagnosed using core clinical criteria, with varying extent of SVD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Frozen CSF samples (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u200a=\u200a84) were measured using Elecsys \u03b2-Amyloid(1\u201342) (A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ), Phospho-Tau (181P) (pTau181), and Total-Tau (tTau) CSF immunoassays, adapted for use on the cobas\n                      <jats:sup>\u00ae<\/jats:sup>\n                      e 411 analyzer (Roche Diagnostics International Ltd), and a robust prototype \u03b2-Amyloid(1\u201340) (A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      ) CSF immunoassay. SVD was assessed by extent of white matter hyperintensities (WMH) using the lesion segmentation tool. Interrelations between WMH, biomarkers, fluorodeoxyglucose F18-positron emission tomography (FDG-PET), and other parameters (including age and Mini-Mental State examinations [MMSE]) were assessed using Spearman\u2019s correlation, sensitivity\/specificity, and logistic\/linear regression analyses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The extent of WMH showed significant correlation with A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      \/A\u03b2\n                      <jats:sub>40<\/jats:sub>\n                      ratio (Rho=-0.250;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u200a=\u200a0.040), tTau (Rho\u200a=\u200a0.292;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u200a=\u200a0.016), tTau\/A\u03b2\n                      <jats:sub>42<\/jats:sub>\n                      ratio (Rho\u200a=\u200a0.247;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u200a=\u200a0.042), age (Rho\u200a=\u200a0.373;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u200a=\u200a0.002), and MMSE (Rho=-0.410;\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u200a=\u200a0.001). Sensitivity\/specificity point estimates for Elecsys CSF immunoassays versus FDG-PET positivity for underlying AD pathophysiology were mostly comparable or greater in patients with high versus low WMH. WMH were not a significant predictor and did not interact with CSF biomarker positivity but modified the association between pTau181 and tTau.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec specific-use=\"heading-level-1\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Elecsys CSF immunoassays detect AD pathophysiology regardless of concomitant SVD and may help to identify patients with early dementia with underlying AD pathophysiology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3233\/jad-221187","type":"journal-article","created":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T12:25:27Z","timestamp":1684499127000},"page":"1537-1549","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Elecsys Cerebrospinal Fluid Immunoassays Accurately Detect Alzheimer\u2019s Disease Regardless of Concomitant Small Vessel Disease"],"prefix":"10.1177","volume":"93","author":[{"given":"Marion","family":"Ortner","sequence":"first","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian","family":"Lanz","sequence":"additional","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Goldhardt","sequence":"additional","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"M\u00fcller-Sarnowski","sequence":"additional","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Diehl-Schmid","sequence":"additional","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"F\u00f6rstl","sequence":"additional","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M.","family":"Hedderich","sequence":"additional","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Yakushev","sequence":"additional","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad A.","family":"Logan","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Philipp","family":"Weinberger","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Simon","sequence":"additional","affiliation":[{"name":"Roche Diagnostics International Ltd","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Grimmer","sequence":"additional","affiliation":[{"name":"Technical University of Munich","place":["Germany"]},{"name":"School of Medicine","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,5,16]]},"reference":[{"key":"e_1_3_6_2_2","first-page":"21","article-title":"Neuropathology of Alzheimer\u2019s disease","author":"Schultz C","year":"2004","unstructured":"SchultzC, DelTredici K, BraakH (2004) Neuropathology of Alzheimer\u2019s disease. In s Disease Current Clinical Neurology, Richter RW, Richter BZ, eds. Humana Press, Totowa, NJ, pp. 21\u201331.","journal-title":"s Disease Current Clinical Neurology"},{"key":"e_1_3_6_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5"},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70156-9"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2012-129026"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1980-5764-2016DN1003002"},{"key":"e_1_3_6_7_2","first-page":"347","article-title":"Pathogenesis of Alzheimer\u2019s disease","volume":"2","author":"Swerdlow RH","year":"2007","unstructured":"SwerdlowRH (2007) Pathogenesis of Alzheimer\u2019s disease. Clin Interv Aging 2, 347\u2013359.","journal-title":"Clin Interv Aging"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-019-0168-6"},{"key":"e_1_3_6_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-019-1498-9"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12816"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70355-6"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1064"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70090-0"},{"key":"e_1_3_6_15_2","first-page":"111","article-title":"Consensus guidelines for lumbar puncturein patients with neurological diseases","volume":"18","author":"Engelborghs S","year":"2017","unstructured":"EngelborghsS, NiemantsverdrietE, StruyfsH, BlennowK, BrounsR, ComabellaM, DujmovicI, van der FlierW, Fr\u00f6lichL, GalimbertiD, GnanapavanS, HemmerB, HoffE, HortJ, IacobaeusE, IngelssonM, Jan de JongF, JonssonM, KhalilM, KuhleJ, Lle\u00f3A, deMendon\u00e7aA, MolinuevoJL, NagelsG, PaquetC, ParnettiL, RoksG, Rosa-NetoP, ScheltensP, Sk\u00e5rsgardC, StomrudE, TumaniH, VisserPJ, WallinA, WinbladB, ZetterbergH, DuitsF, TeunissenCE (2017) Consensus guidelines for lumbar puncturein patients with neurological diseases. Alzheimers Dement(Amst) 18, 111\u2013126.","journal-title":"Alzheimers Dement(Amst)"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170680"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.05.2243"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.01.010"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-200210000-00001"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0206-2"},{"key":"e_1_3_6_22_2","doi-asserted-by":"publisher","DOI":"10.1159\/000488705"},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70124-8"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-013-0415-7"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.009475"},{"key":"e_1_3_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.01.016"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-018-0515-3"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00927"},{"key":"e_1_3_6_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.754"},{"key":"e_1_3_6_30_2","first-page":"e12050","article-title":"Alzheimer\u2019s disease drug development pipeline: 2020","volume":"6","author":"Cummings J","year":"2020","unstructured":"CummingsJ, LeeG, RitterA, SabbaghM, ZhongK (2020) Alzheimer\u2019s disease drug development pipeline: 2020. Alzheimers Dement 6, e12050.","journal-title":"Alzheimers Dement"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijs.12466"},{"key":"e_1_3_6_32_2","unstructured":"ClinicalTrials.gov NCT02477800: 221AD301 phase 3 Study of aducanumab(BIIB037) in early Alzheimer\u2019s disease (ENGAGE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477800 Last updated September 2 2021 Accessed on March 14 2023."},{"key":"e_1_3_6_33_2","unstructured":"ClinicalTrials.gov NCT02484547: 221AD302 phase 3 Study of aducanumab(BIIB037) in early Alzheimer\u2019s disease (EMERGE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484547 Last updated September 2 2021 Accessed on March 14 2023."},{"key":"e_1_3_6_34_2","unstructured":"ClinicalTrials.gov NCT03443973: Safety and efficacy study ofgantenerumab in participants with early Alzheimer\u2019s disease (AD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03443973 Last updated January 9 2023 Accessed on March 14 2023."},{"key":"e_1_3_6_35_2","unstructured":"ClinicalTrials.gov NCT03444870: Efficacy and safety study ofgantenerumab in participants with early Alzheimer\u2019s disease (AD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03444870 Last updated February 9 2023 Accessed on March 14 2023."},{"key":"e_1_3_6_36_2","unstructured":"ClinicalTrials.gov NCT03887455: Study to confirm safety andefficacy of lecanemab in participants with early Alzheimer\u2019s disease(Clarity AD) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03887455 Last updated December 15 2022 Accessed on March 14 2023."},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.6.1508"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.9.1159"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2011.11.032"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70299-6"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01003-w"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2019.06.180328"},{"key":"e_1_3_6_44_2","unstructured":"The European Joint Action on Dementia (2013) ALzheimer COoperativeValuation in Europe (ALCOVE) Synthesis Report https:\/\/www.alcove-project.eu\/images\/pdf\/ALCOVE_SYNTHESIS_REPORT_VF.pdf Last updated not stated Accessed on March 14 2023."},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/gps.4997"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150692"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30367-6"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60461-5"},{"key":"e_1_3_6_49_2","unstructured":"Roche (2018) FDA grants Breakthrough Device Designation for \u2019sElecsys cerebrospinal fluid (CSF) assays tosupport the improved diagnosis of Alzheimer\u2019s disease https:\/\/assets.cwp.roche.com\/imported\/857494.pdf Last updated 20July 2018 Accessed on March 14 2023."},{"key":"e_1_3_6_50_2","unstructured":"Roche Diagnostics (2022) Alzheimer\u2019s disease CerebrospinalFluid (CSF) assays receive FDA clearance supporting more accurateand timely diagnosis https:\/\/diagnostics.com\/us\/en\/news-listing\/2022\/-alzheimers-disease-cerebrospinal-fluid-assays-receive-fda-clearance.html Last updated March 14 2023 Accessed on March 14 2023."},{"key":"e_1_3_6_51_2","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S90871"},{"key":"e_1_3_6_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.11.008"},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.12.008"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-210534"},{"key":"e_1_3_6_55_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000916"},{"key":"e_1_3_6_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12511"},{"key":"e_1_3_6_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.915405"},{"key":"e_1_3_6_58_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7559"},{"key":"e_1_3_6_59_2","doi-asserted-by":"publisher","DOI":"10.1177\/17474930221137019"},{"key":"e_1_3_6_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12236"},{"key":"e_1_3_6_61_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.17363"},{"key":"e_1_3_6_62_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4249"}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-221187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.3233\/JAD-221187","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.3233\/JAD-221187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T07:40:53Z","timestamp":1781854853000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.3233\/JAD-221187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,16]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6,13]]}},"alternative-id":["10.3233\/JAD-221187"],"URL":"https:\/\/doi.org\/10.3233\/jad-221187","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,16]]}}}